Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
Pfizer
Pfizer
M.D. Anderson Cancer Center
MedImmune LLC
NeoImmuneTech
Providence Health & Services
Medical University of South Carolina
University of Michigan Rogel Cancer Center
University of California, Davis
Dizal Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
Takeda
Big Ten Cancer Research Consortium
Exelixis
Pfizer
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Medical University of South Carolina
Alaunos Therapeutics
BerGenBio ASA
Incyte Corporation
National Cancer Institute (NCI)
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Bristol-Myers Squibb
City of Hope Medical Center
Formation Biologics
Hoffmann-La Roche
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
Aprea Therapeutics
NextCure, Inc.
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Syndax Pharmaceuticals
Bristol-Myers Squibb
Spanish Lung Cancer Group
National Cancer Institute (NCI)
BerGenBio ASA
Sarcoma Oncology Research Center, LLC
Astellas Pharma Inc
National Cancer Institute (NCI)
AstraZeneca
GlaxoSmithKline
NantCell, Inc.
Pfizer
University of California, San Diego
Haihe Biopharma Co., Ltd.
Georgetown University